Disclosed are compounds of Formula I 1
and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2,
R.sub.3, R.sub.4, and R.sub.5 are defined herein. These compounds are
useful for treating diseases and conditions caused or exacerbated by
unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical
compositions containing the compounds, methods of preparing the compounds
and methods of treatment using the compounds are also disclosed.
